NVO
NYSE · Healthcare
Novo Nordisk A/S
$39.40
-0.40 (-1.01%)
NVO News30 articles
Viking Surges 24% as Monthly VK2735 Retains 85% Weight Loss
Viking Therapeutics (VKTX) soared 24% premarket after monthly VK2735 dosing preserved 85% of prior weight loss, signaling strong potential for its obesity pipeline.
Novo Nordisk Shares Plunge 8% as Investors Question Post-Semaglutide Growth Strategy
Novo Nordisk ADRs dropped 8.18% to $39.705 after its capital markets day, as investors questioned how it will offset the 2032 U.S. semaglutide patent expiry. The company targets over DKK 150B in pipeline sales by 2035.
Tech Rally Lifts Nasdaq as Oil Slump Eases Rate Anxiety
U.S. stocks rallied Monday as oil prices fell nearly 4% and Treasury yields eased, lifting the Nasdaq 1.57%. Intel and AMD surged, leading tech gains.
Novo Nordisk Shares Drop 5% as 2030 Strategy Omits Growth Target
Novo Nordisk shares slid 5% after its 2030 strategy omitted a numeric growth target, focusing instead on pipeline diversification and launches.
Novo Nordisk Faces Semaglutide Test at Capital Markets Day
Novo Nordisk's Capital Markets Day on Monday will test its strategy as semaglutide dominates sales. Stock closed at $43.24, with analysts split on valuation.
Kailera Shares Slip 12.5%, Valuation Nears Cash Position
Kailera shares dropped 12.5% to $16.21, leaving valuation barely above IPO price and close to cash per share. Pipeline catalysts in 2027.
Lilly Stock Slips Despite Mounjaro Heart Approval
Eli Lilly shares dipped 0.9% despite FDA approval for Mounjaro to cut heart risks, as investors had already priced in the news. Sales still surged 91%.
Eli Lilly Stock Nears Analyst Targets After $67B Rally
Eli Lilly's shares have rallied 6.38% over the past week, adding $67B in market value, bringing the stock within 4.4% of analysts' consensus target.
Roche Jumps on $9B Breast Cancer Drug Forecast
Roche shares gained 1.5% after Morgan Stanley forecast CHF9B peak sales for its breast cancer drug giredestrant, a bullish signal for the pharma giant.
Eli Lilly Stock Near Record as Volume Surge Offsets Price Cuts
Eli Lilly (LLY) nears all-time high as Q2 volume surges 60%, offsetting a 13% price drop. Mounjaro and Zepbound account for 64% of revenue.
Novo Nordisk Gains 1.9% as Medicare Wegovy Copay Trial Raises Pricing Questions
Novo Nordisk's ADR gained 1.85% to $45.71 as Medicare's GLP-1 Bridge offers Wegovy at $50 monthly, but analysts see limited upside with all Holds.
Novo Nordisk Outlook Upgrade Fails to Lift Shares as Analysts See Slim Gains
Novo Nordisk stock slipped 2.9% last week even after management raised its 2026 guidance. Analysts see only 2.2% upside, with most rating the stock a Hold.
Eli Lilly Defends Obesity Drug Pipeline Amid Retatrutide Lawsuits
Eli Lilly shares rose 0.5% as the company filed six lawsuits against unauthorized sellers of its experimental obesity drug retatrutide, reinforcing its commitment to pipeline integrity.
Lilly's Foundayo Wins UK Approval, Lifting Shares Nearly 3%
Eli Lilly's (LLY) shares jumped 2.9% after the UK became the first European country to approve its oral weight-loss drug Foundayo, adding about $30 billion to its market value.
Lilly's Q2 Growth Hinges on Mounjaro, Zepbound as Sales Projection Leans Heavily on Weight-Loss Franchise
Eli Lilly (LLY) is set to report Q2 earnings Wednesday, with Mounjaro and Zepbound expected to contribute 98% of revenue growth. Pre-market shares rose 2.2% after a five-day slide.
Novo Nordisk Slips 4% as Profit Beat Fails to Quell Wegovy Worries
Novo Nordisk shares dropped 4% in Copenhagen after Q2 profit beat estimates, but concerns over Wegovy and pipeline setbacks weighed on sentiment.
Amgen Lifts 2026 Forecast as Five Growth Brands Offset $772M Slump
Amgen (AMGN) raised its 2026 guidance after Q2 revenue beat estimates, as five growth brands added $923M in sales, offsetting a $772M decline from five struggling products.
Novo Nordisk ADR Slides Despite Strong Q2, Danish Shares Await Catch-Up
Novo Nordisk's ADR dropped 6.8% despite Q2 earnings surpassing forecasts, as investors weigh pipeline impairments and competitive pressures.
Hims & Hers Stock Rebounds 11% Ahead of Q2 Earnings Test
Hims & Hers shares surged 11% before earnings, erasing FTC-related losses. The focus now shifts to margin recovery and Eucalyptus integration.
Novo Nordisk Shares Plunge 9% as ZEUS Trial Fails to Show Cardiovascular Benefit
Novo Nordisk shares fell sharply after ZEUS trial data showed no significant cardiovascular benefit, wiping out $20.5 billion in market cap and underscoring heavy reliance on GLP-1 franchise.
Altimmune Shares Jump on Positive Alcohol-Use Disorder Trial Data, Warrant Exercise in Focus
Altimmune shares surged following positive Phase 2 results for pemvidutide in alcohol-use disorder, with the stock price triggering $225 million in warrants.
Viking Therapeutics Faces Cash Runway Questions Ahead of Q2 Report
Viking Therapeutics shares fell 6.2% last week as analysts increased Q2 loss estimates by 24% to $1.23 per share. The company's cash runway faces scrutiny ahead of earnings on July 29.
Eli Lilly's $50 Obesity Drug Strategy: Volume vs. Price
Eli Lilly's stock hovers near record highs as a new Medicare program offers $50/month access to its obesity drugs. First-quarter revenue surged 56%, but lower realized prices trimmed growth.
Novo Nordisk B Shares Lag OMXC25 as Low Volume Clouds Rally Ahead of H1 Report
Novo Nordisk B shares rose 2.8% last week but lagged the broader Danish market. Low volume raises caution ahead of August H1 results.
Novo Nordisk Shares Decline as Medicare Caps Wegovy Pricing
Novo Nordisk shares slipped 1.36% as Medicare's new GLP-1 Bridge program caps Wegovy pricing at $245 monthly net, limiting revenue upside despite strong prescription growth.
Microsoft Stock Rises on $2.5B AI Unit Launch, Outpaces Nasdaq
Microsoft shares climbed 1.62% to $390.49, boosted by its $2.5 billion Frontier AI unit, while the Nasdaq fell 0.80%. The gain added $46.1 billion in market value.
Hims & Hers Shares Surge on Canaccord Upgrade Amid GLP-1 Shift
Hims & Hers shares climbed 9.5% to $37.97 after Canaccord Genuity raised its target to $40, reflecting a 25% bump. The company's GLP-1 strategy and Medicare's new Bridge program are reshaping the weight-loss drug market.
Pfizer Gains on China GLP-1 News, but Dividend Focus Limits Upside
Pfizer shares edged up 0.4% after its GLP-1 drug cleared a China insurance review, but the stock trails the S&P 500 as investors weigh dividend yield against growth prospects.
Novo Nordisk B Shares Surge on South African Court Ruling Against Compounder
Novo Nordisk B shares surged 9.9% in three sessions after a South African court halted iDexis from supplying compounded semaglutide, potentially shifting demand to Novo.
Viking Therapeutics Surges on Obesity Drug Hopes
Viking Therapeutics shares climbed 6% to $34.30 as investors bet on upcoming Phase 3 data for its obesity drug VK2735, expected in Q3 2026.